The high prevalence of preexisting immunity to the commonly used adenoviral vectors, as well as the requirement for readministration of vector for multiple therapeutic applications, necessitates the development of a panel of immunologically distinct adenoviral vectors against which neutralizing antibodies are rare in human populations. We have completely sequenced three chimpanzee-derived adenoviruses, Pan 5, Pan 6, and Pan 7, and have molecularly cloned E1-deleted vector genomes from each as bacterial plasmids. All the E1-deleted vectors were grown to high titer in HEK 293 cells. Neutralizing antibodies to the chimpanzee adenoviral vectors were not detected in serum samples from human subjects. In vitro cross-neutralization using rabbit antisera and in vivo readministration experiments in mice demonstrated that antibodies against Pan 5, Pan 7, or Pan 9 cross-neutralize one another but do not neutralize Pan 6. These results indicate that chimpanzee adenoviral vectors may be useful as vaccines or gene therapy vectors in human populations and should allow applications that require multiple vector administrations.
INTRODUCTION P
ROPERTIES OF ADENOVIRUSES that have made them attractive as vectors for human gene therapy and genetic vaccines include relative promiscuity in tissue tropism, high-level expression of the transgene, and ease in producing high-titer virus. However, these advantages are considerably mitigated by the fact that a large proportion of human subjects have preexisting antibodies to the subgroup C adenoviruses (Vogels et al., 2003) , which are the best understood biologically, and have been used in the construction of the great majority of existing vectors (Wivel et al., 1999) . Those subjects who do not have detectable humoral immunity quickly develop antibodies that effectively preclude the possibility of efficaciousreadministrationof a vector of the same serotype. Adoption of subgroup C adenoviruses, such as serotypes 2 (AdHu2) and 5 (AdHu5), for the development of gene therapy has been facilitated by growth properties that make them comparatively easy to purify and to study in the laboratory, as well as the availability of HEK 293 cells, which express AdHu5 E1 region genes (Graham et al., 1977) and support the propagation of E1-deleted AdHu5 (and the closely related AdHu2) vectors.
One successful approach toward administering adenoviral vectors in populations with preexisting immunity due to natural infections or prior vector exposure is to develop a catalog of vectors based on virus serotypes to which the subject is unlikely to have been exposed. This is especially relevant for vaccine strategies requiring efficacy in a high percentage of the population, and multiple administrations of vector to effectively boost immune responses. Several groups have pursued this ap-proach by developing vectors based on rare human serotypes, such as serotype 35 (Vogels et al., 2003) , or by using nonhuman adenovirusesderived from bovine, canine, or ovine sources (Mittal et al., 1995; Xu et al., 1997; Kremer et al., 2000) . We used an adenovirus called Pan 9 (AdC68), originally isolated from a chimpanzee, and generated a vector similar to currently used adenoviral vectors by deleting the E1 region (Farina et al., 2001) . The E1 functions of this virus were efficiently complemented by the AdHu5 E1 genes expressed in HEK 293 cells, and therefore the virus could be grown in these cells by standard methods. Here we describe the extension of this approach whereby vectors based on three other chimpanzee adenoviruses, Pan 5, Pan 6, and Pan 7, were constructed as bacterial plasmid clones after complete sequencing of the respective genomes. We have explored the immunological relatedness of the four chimpanzee adenoviruses by in vitro and in vivo cross-neutralization experiments.
MATERIALS AND METHODS
Chimpanzee adenoviruses Pan 5 (VR-591; American Type Culture Collection [ATCC] , Manassas, VA), Pan 6 (VR-592; ATCC), Pan 7 (VR-593; ATCC), and Pan 9 (VR-594; ATCC) were purchased. (The Universal Virus Database of the International Committee on Taxonomy of Viruses has listed Pan 5, Pan 6, Pan 7, and Pan 9 as simian adenovirus 22, simian adenovirus 23, simian adenovirus 24, and simian adenovirus 25, respectively.)Virus stocks were obtained and propagated in 293 cells and purified, and genomic DNA was purified by standard methods as described (Farina et al., 2001) .
Sequence analysis of Pan 5, Pan 6, and Pan 7 viral genomes
Viral genomic DNA was isolated for Pan 5, Pan 6, and Pan 7 and subjected to sequence analysis by generating a whole genome shotgun library for each virus. Complete sequencing was achieved with 4-to 6-fold coverage (Qiagen Genomics Services, Bothell, WA).
Creation of infectious molecular clones of E1-deleted vectors based on Pan 5, Pan 6, Pan 7, and Pan 9
To construct and clone E1-deleted vectors, a strategy was devised whereby the left end of the viral genome harboring the E1 region was initially cloned as an approximately 3.6-kb (Pan 5, Pan 7, and Pan 9, up to an FseI site) or 6-kb (Pan 6, up to an XbaI site) fragment. The integrity of the left terminus of the cloned DNA was confirmed by comparing the sequence with that of other adenovirus inverted terminal repeat (ITR) ends. The early region 1 (E1) open reading frames of Pan 7 were disrupted by deleting a 2.5-kb fragment between SnaBI and NdeI ( Fig. 1 ) sites and replacing it with a polymerase chain reaction (PCR) fragment amplified from an expression cassette of Aequorea victoria green fluorescent protein (GFP) gene directed by the prokaryotic b-galactosidase promoter (pkGFP) and flanked with restriction sites for I-CeuI and PI-SceI (Fig. 2) . This removes the entire E1a and E1b 21-kDa homolog-coding regions as well as 74% of the E1b 55-kDa homolog-coding region. The remainder of each chimpanzee adenovirus genome was inserted in sequential cloning steps so as to assemble the complete (E1-deleted) Pan 5, Pan 6, Pan 7, and Pan 9 genomes harboring a GFP cassette under the control of a prokaryotic promoter (pC5-pkGFP, pC6-pkGFP, pC7-pkGFP, and pC68-pkGFP, respectively). A representative plasmid map of pC7-pkGFP is shown in Fig. 2 . To generate infectious viral vectors, plasmid DNAs were digested with the appropriate restriction enzyme to release viral DNA ends for transfection into an E1-complementing cell line such as HEK 293.
Generation and characterization of vectors based on chimpanzee adenoviruses
A highly efficient direct cloning and green/white selection procedure was employed to create molecular clones of recombinant viruses . Briefly, a gene of interest was cloned into the multiple cloning site of the plasmid pShuttle (BD Biosciences Clontech, Palo Alto, CA) so that it could be reexcised with the extremely rare cutter enzymes I-CeuI and PI-SceI and transferred into a chimpanzee adenovirus plasmid, by exchanging it with the pkGFP cassette (flanked by I-CeuI and PI-SceI sites) and screening white colonies for correct recombinants. To rescue recombinant virus, the plasmid molecular clones of chimpanzee adenoviral vectors were digested with the appropriate restriction enzyme that releases the viral DNA ends and transfected into 293 cells. The viruses were purified by a standard CsCl sedimentation method. Plaque formation unit (PFU) and replication-competent adenovirus(RCA) assays for all vectors were performed on 293 and A549 cells, respectively, as described previously (Gao et al., 1996 (Gao et al., , 2000 .
In vivo transduction by chimpanzee adenoviral vectors in murine models
Chimpanzee adenoviruses Pan 6, Pan 7, and Pan 9 (C68) as well as AdHu5-based E1-deleted vectors carrying the human a 1 -antitrypsin (A1AT) or b-galactosidase transgene driven by the cytomegalovirus (CMV) immediate-early gene promoter were administered to 5-to 6-week-old BALB/c or NCR nude mice (Taconic, Germantown, NY) by intravenous, intramuscular, or intratracheal routes of administration at a dose of 10 11 viral particles per mouse to target liver, muscle, or lung tissue, respectively. The animals were killed 3 days later for assessment of gene transfer by the measurement of human A1AT levels (for animals that had been administered A1AT vectors) and by 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal) histochemical staining of target tissue cryosections (for animals that had received LacZ vectors) (Gao et al., 1996) .
Serological analysis of chimpanzee adenoviruses
To generate rabbit polyclonal antisera against the various chimpanzee viruses, vectors based on Pan 5, Pan 6, Pan 7, and Pan 9 (AdC68) and expressing the GFP protein directed by the CMV promoter (AdC5GFP, AdC6GFP, AdC7GFP, and AdC68GFP, respectively) were administered to the quadriceps muscle of New Zealand White rabbits at a dose of 10 13 viral particles followed by a boost with an equal dose with Freund's incomplete adjuvant 34 days later. The animals were terminally bled 14 days after the boost to collect antiserum. Serum samples from 52 human volunteers and 110 other primates of different species were also collected. Sera were analyzed for the presence of neutralizing antibodies by assessing the ability of serum to inhibit transduction of 293 cells by a reporter virus (expressing GFP) of the serotype being tested. Specifically, the reporter virus for each serotype was incubated with dilutions of heat-inactivated sera from immunized rabbits, or from the animal and human sera under test. After a 1-hr incubation at 37°C, viruses were added to 293 cells in 96-well plates (at a multiplicity of infection of 10 4 viral particles per cell) for 24 or 48 hr, depending on the virus serotype. 
FIG. 2.
Plasmid map of the molecular clone of the E1-deleted chimpanzee adenoviralvector AdC7, carrying the green fluorescent protein gene driven by a prokaryotic b-galactosidase promoter (pkGFP). Minigene cassettes of interest flanked by I-CeuI and PI-SceI sites in a shuttle plasmid can be easily swapped with the pkGFP cassette by green/white selection. To create the E1/E3-deleted chimpanzee adenoviral vectors, the E3 region between the AvrII and NruI sites shown was removed from E1-deleted molecular clones of the AdC7 backbone. The AdC7-DE1/DE3 vector was rescued and propagated in 293 cells. The map of the Pan 7-based vector is shown; the same strategy was used for the construction of vectors based on Pan 5, Pan 6, and Pan 9.
tralizing antibody titers were reported as the highest serum dilution that inhibited transduction to less than 50%. Equal quantities of each vector, in terms of total particles, were used in the assay despite each showing different transduction efficiencies. This was designed to facilitate a comparison of relative prevalence of neutralizing antibodies across all vector serotypes.
RESULTS

Analysis of early region genes for the creation of recombinant vectors
Sequence analysis of chimpanzee adenoviruses Pan 5, Pan 6, and Pan 7 revealed them to be closely related to, and similar in genome structure to, that described for Pan 9 (AdC68) (Farina et al., 2001) . Examination of the E1 region of chimpanzee adenoviruses Pan 5, Pan 6, and Pan 7 (Fig. 1 ) revealed similarities to human adenoviruses, with the greatest overall similarity to AdHu4. A likely common splice acceptor site, analogous to that present in other adenovirus E1a genes, was found, as well as the three splice donor locations that may give rise to the RNAs corresponding to the 13S, 12S, and 9S RNAs of AdHu2. Translation of the putative 13S transcript results in a 256-amino acid product (Pan 5) or a 258-amino acid product (Pan 6 and Pan 7) that is 75% identical to the E1a product of adenovirus serotype 4 (AdHu4). The E1b region of the three chimpanzee adenoviruses contains the two open reading frames that encode products homologous to the AdHu2 E1b 19-and 55-kDa proteins, respectively. Of the published adenovirus sequences, they are the most homologous to the E1b proteins of AdHu4 and adenovirus serotype 7. The common polyadenylation site for E1b and protein IX RNAs was identified.
The extent of the deletion in E1 that was made in the chimpanzee viruses is shown in Fig. 1 . A 2.5-kb segment between the restriction enzyme sites SnaBI and NdeI (that are common to all three adenoviruses) was removed. The proximity of the E1b and protein IX genes complicates creation of E1-deleted vectors. In AdHu5, the promoter for protein IX is located within E1b-coding sequences. The 39 boundary of E1 deletions engineered into the chimpanzee viruses was located well upstream of the start codon for protein IX (about~bp 475) in order to maintain adequate promoter activity in view of the absence of a TATA-like sequence in the chimpanzee adenoviruses to help mark protein IX transcriptional initiation. Development of vectors from the chimpanzee adenoviruses would be greatly facilitated through the use of available E1-expressingcell lines, such as HEK 293 cells, which are used to propagate the commonly used human adenoviral vectors. The E1-deleted AdC68 (Pan 9) adenovirus has previously been shown to propagate to wildtype levels in HEK 293 cells, which express AdHu5 E1 proteins (Farina et al., 2001) . The extent of sequence homology in E1 proteins between AdHu5 and AdC68 is similar to that between AdHu5 and Pan 5, Pan 6, and Pan 7 and, as described below, HEK 293 cells were found to adequately complement the E1 functions of these adenoviruses as well.
In addition to creating E1 deletions, chimpanzee adenoviral vectors with deletions in the E3 region have also been constructed (Fig. 1) . Because the E3 region is known to encode genes that are not required for propagation of the virus in culture, deletion of E3 sequences in addition to the deletion of E1 can be used to increase the cloning capacity of the adenoviral vectors without requiring modifications in the cell line used to grow the vector. Toward this end, we have made molecular clones based on Pan 6, Pan 7, and Pan 9 (AdC68) in which both E1 and E3 have been deleted. To create the E3-deleted vectors, a 3.5-kb deletion between the NruI and AvrII restriction enzyme sites, which are present in all four vectors (Fig. 1) , was made that disrupts seven of the nine open reading frames (i.e., other than the AdHu5 12.5-and 14.5-kDa E3 homologs) present in the E3 region.
Molecular clones and recombinant viruses
To use the chimpanzee adenoviruses as vectors, it is highly desirable to have molecular clones of the viral DNA as bacterial plasmids. This provides a means to completely eliminate the possibility of carrying over contaminating infectious material from the original hosts, which are known to have harbored agents such as prions (Rogers et al., 1967; Basnight et al., 1971) , and to ensure the purity of the adenoviral vector stock. Molecular cloning of the complete adenovirus genome would also facilitate the construction of new vectors by standard molecular biology techniques. Although it is possible to obtain recombinant adenovirus by in situ recombination from two separate bacterial plasmids, it is more desirable to construct the complete genome as a plasmid without recourse to recombination; this ensures that the recombinant adenovirusis truly clonal in nature. Cloning strategies (as described in Materials and Methods) were devised for Pan 5, Pan 6, and Pan 7 on the basis of sequence information. Execution of these strategies has resulted in the successful construction of plasmids harboring the complete adenoviral vector genomes for Pan 5, Pan 6, and Pan 7, as well as Pan 9 (AdC68). The gene transfer vectors based on them are designated AdC5, AdC6, AdC7, and AdC68, respectively. A representative plasmid map of the molecular clone of AdC7-pkGFP (pC7-pkGFP) is shown in Fig. 2 .
To facilitate identification of bacterial colonies harboring plasmids with inserted transgenes of interest, a convenient green/white selection method was employed . Briefly, the GFP-expressing parental plasmid renders the host (Escherichia coli) green; excision of the GFP cassette and insertion of a transgene expression cassette between the rare cutter I-CeuI and PI-SceI sites results in nonfluorescent bacterial colonies. Transfection of each of the newly constructed adenovirus plasmids into HEK 293 cells was found to result in the formation of infectious virus, thereby confirming the expectation that the E1 deletion in these chimpanzee adenoviruses could be complemented in trans by AdHu5 E1 found in HEK 293 cells.
For adenoviral vectors to be useful in therapeutic applications, it is important that the yield of virus be high and that the resulting preparationsare biologicallyactive. Although we were able to propagate the chimpanzee-derived adenoviral vectors in the human cell line HEK 293, it was of interest to determine the vector yields of the chimpanzee adenoviral vectors compared with AdHu5 vectors. Cumulative data from several largescale preparations purified by cesium chloride gradient centrifugation of each of the four chimpanzee adenoviral vectors (AdC5, AdC6, AdC7, and AdC68, harboring various trans-
FIG. 3.
Comparison of particle (pt) yields and particle-to-PFU ratios for vectors derived from human (AdHu5) and chimpanzee adenoviruses. (Vectors derived from Pan 5, Pan 6, Pan 7, and Pan 9 are designated C5, C6, C7, and C68, respectively.) Vector preparations were generated from 1 3 10 9 293 cells and purified by the CsCl sedimentation method. Particle numbers were obtained by OD 260 measurements and plaque-forming units (PFU) were determined by plaque assay on 293 cells as described previously. The sample pools represent total vectors produced by the Gene Therapy Program Vector Core irrespective of different transgenes. The percentage of the total number in the individual sample pools is indicated above each column. The total number of vectors analyzed by serotype was as follows: AdHu5, 528; AdC5, 8; AdC6, 47; AdC7, 49; AdC68, 44. genes) are shown in Fig. 3 
13 particles per fifty 150-cm 2 plates. AdC7 and AdC68 yields tended to be slightly higher than those obtained for human Ad5 vectors. It is interesting to note that the overall homology in the E1 proteins between AdHu5 and chimpanzee adenoviruses is about 45% for the E1a 13S product, 55% for the E1b small T protein, and 70% for the E1b large T protein. Homology in the E1a conserved domains CR1, CR2, and CR3 between AdHu5 and the chimpanzee adenoviruses is about 63, 74, and 70%, respectively. This degree of homology is thus sufficient for adequate complementation by 293 cells with respect to the final yield of the vectors in a large-scale preparation. However, the infectivity of the chimpanzee-based vectors, as assessed by measuring the particle-to-PFU ratio in 293 cells, differed significantly from that of AdHu5 vectors (Fig. 3) . The center of the distribution curve for AdHu5 particle-to-PFU ratios is between 10 and 200, whereas for chimpanzee-based vectors the majority of these ratios exceed 200. This apparent diminution in infectivity of the chimpanzee vectors versus AdHu5 vectors is due to either a real decline in potency or to a relatively inefficient ability of 293 cells to support plaque formation. To determine transduction potency in vitro, the efficiency with which the chimpanzee adenoviral vectors are able to transduce three different cells lines was tested by measuring LacZ expression in limiting dilution infections. Transduction with the chimpanzee adenoviral vectors was similar to that obtained with LacZ vectors based on AdHu5 (Fig. 4) . This result suggests that the relative infectivity of the chimpanzee adenoviral vectors is similar to that of AdHu5 vectors and that inefficient plaque formation on 293 cells is responsible for the higher particle-to-PFU ratios of the chimpanzee-based vectors.
Because 293 cells harbor the left 4344 bp of the AdHu5 genome (Louis et al., 1997) containing the E1 locus, propagation of AdHu5-based vectors in these cells leads to the ready generation of RCA because of the restoration of AdHu5 E1 sequences to the vectors by homologous double recombination. It has previously been suggested that continuous stretches of sequence identity in excess of 100 bp are required for the efficient initiation of homologous recombination (Waldman and Liskay, 1988) . This has been confirmed for RCA emergence as well (Robert et al., 2001) . In view of this, it is of interest to examine the extent of homology that remains between the AdHu5 E1 sequence present in 293 cells and the E1-deleted chimpanzee adenoviral vectors (Fig. 5) . The homology present to the left and right of the E1 deletion was between 60 and 65% and the longest stretch of continuous sequence identity was 19 bp to the left and 20 bp to the right of the E1 deletion. Reduction of homology to 29 bp has been shown to prevent the emergence of detectable RCA (Robert et al., 2001) and, as expected, we have not detected the emergence of RCA in our chimpanzee adenovirus preparations (data not shown).
Biology of chimpanzee adenoviral vectors in gene transfer
The efficiency of gene transfer of the three new chimpanzee adenoviral vectors based on Pan 5, Pan 6, and Pan 7 in mice was quantified with human a 1 -antitrypsin (A1AT)-expressing vectors administered locally by intramuscular injection and into the trachea as well as systemically by tail vein injection. Vector-directed A1AT expression was monitored in 6-week-old NCR nude mice (five mice per group) by determining A1AT secreted into the plasma by transduced cells, using an enzymelinked immunosorbentassay (ELISA) for human A1AT. To test the efficacy of intramuscular gene transfer, the chimpanzee adenovirus and AdHu5 vectors were administered intramuscularly into the tibialis anterior muscle, using a dose of 10 11 viral particles per mouse. Intratracheal administration was also done by instillation of 10 11 viral particles per mouse. To test the efficacy of gene transfer after intravenous administration, the same dose of vector was administered by tail vein injection into 6-week-old BALB/c mice. The plasma levels of human A1AT were determined 3 days later (Fig. 6) . It is clear that the efficiency of transduction of the chimpanzee adenoviral vectors into skeletal muscle is equivalent to that seen for the AdHu5- based vector. However, plasma levels of A1AT after intravenous administration were 2 logs less than that seen for the AdHu5-based vector. AdHu5-based vectors injected systemically into mice are known to be predominantly sequestered in the liver sinusoidal system, resulting in high levels of liver gene transfer to Kupffer cells and hepatocytes. The equivalence of gene expression after skeletal muscle-directedgene transfer and intravenous administration is clearly in contrast to observations with the AdHu5 vector.
The efficiency of gene transfer in mice of the three new chimpanzee adenoviral vectors based on Pan 5, Pan 6, and Pan 7 was also determined, using b-galactosidase-expressing vectors. Six-week-old NCR nude mice were administered 10 11 particles of AdC5CMVLacZ, AdC6CMVLacZ, AdC7CMVLacZ, or AdHu5CMVLacZ by three different routes including systemic injection (via the tail vein), intramuscular injection (via the hind limb), or intratracheal instillation (via the lung). Three days later, the appropriate tissue was harvested (i.e., liver for systemic administration, muscle from the site of intramuscular injection, and lungs from mice treated intratracheally)and stained for b-galactosidase activity, using X-Gal. Representative fields are shown in Fig. 7 . As deduced from transgene expression levels when using the A1AT expression vector, although in vivo transduction efficiencies of all the viruses including AdHu5 were similar in lung and muscle, the chimpanzee adenoviral vectors were less efficient than AdHu5 in gene transfer to the liver. Therefore the absence of high levels of liver transduction after systemic administration of the chimpanzee adenoviralvectors was probably the cause of lower serum levels of A1AT after tail vein injection compared with that seen with AdHu5 vectors.
Serologic characterization of simian viruses
To determine the degree of serological relatedness of the chimpanzee adenoviruses, high-titer antibodies were raised against each of the viruses in rabbits. The neutralization titers of each antiserum against the four chimpanzee adenoviruses are shown in Table 1 . It was found that vectors based on Pan 5, Pan 7, and Pan 9 (AdC5GFP, AdC7GFP, and AdC68GFP, respectively) could be neutralized by antisera raised against any one of these three viruses. On the other hand, the Pan 6-based vector AdC6GFP could be neutralized only by serum raised against itself.
Successful administration of adenoviral vectors is greatly compromised in the presence of preexisting neutralizing antibodies. The prevalenceof neutralizingantibodies to chimpanzee adenoviruses in human populations is expected to be low. Serum samples from 51 normal human volunteer donors, 52 rhesus macaques, and 20 chimpanzees were tested for their ability to neutralize GFP-expressing vectors AdC5GFP, AdC6GFP, AdC7GFP, and AdC68GFP (Table 2 ). The presence of antibodies to AdHu5 was also tested in the same assay. As expected, the human samples frequently harbored antibodies against AdHu5. However, antibodies capable of neutralizingthe chimpanzee adenoviruses were rare and, when present, of low titer, in contrast to the frequent presence of high-titer antiAdHu5 neutralizing antibodies (data not shown).
The serological dissimilarity of the Pan 6-derived vector from the other chimpanzee adenoviral vectors was further evaluated in the context of in vivo gene transfer experiments. C57BL/6 mice were first immunized intramuscularly with LacZ-expressing vectors of each of the chimpanzee adenovirus serotypes as well as AdHu5. This was followed 30 days later by intravenous administrationof vectors expressing A1AT (Fig.  8) . To determine the efficacy of vector readministration, A1AT ROY ET AL.
FIG. 6.
Comparison of gene transfer to murine liver, muscle, and lung tissues mediated by different chimpanzee and human adenoviral vectors expressing a 1 -antitrypsin (hA1AT). Equal numbers of viral particles (10 11 ) of AdHu5CMVA1AT, AdC6CMVA1AT, AdC7CMVA1AT, and AdC68CMVA1AT (labeled AdHu5, AdC6, AdC7, and AdC68, respectively) were administered by tail vein injection to 6-week-old BALB/c mice (top), to the hind limb tibialis anterior muscle tissue of 6-weekold NCR nude mice (middle), or by intratracheal instillation into 6-week-old NCR nude mice (bottom). Plasma levels of A1AT were determined 3 days after vector administration.Data shown are the average of five mice per group.
FIG. 7.
Comparison of gene transfer to murine liver, lung, and muscle tissue mediated by various chimpanzee and human adenoviral vectors expressing b-galactosidase. Equal numbers of viral particles (10 11 ) of AdHu5CMVLacZ, AdC6CMVLacZ, AdC7CMVLacZ, and AdC68CMVLacZ (labeled AdHu5, AdC6, AdC7, and AdC68, respectively) were administered to liver, lung, and skeletal muscle tissue of 6-week-old NCR nude mice via intravenous, intratracheal, and intramuscular injection. The tissues were harvested on day 3 after vector treatment for cryosectioning and histochemical staining with X-Gal. levels in serum samples were measured 3 days after the second gene transfer. As expected, previous exposure to AdHu5 did not prevent vector transduction with any of the chimpanzee adenoviral vectors. However, the vectors derived from Pan 5, Pan 7, and Pan 9 (AdC5, AdC7, and AdC68, respectively) appear to be serologically related in that previous exposure to one of these vectors prevented transduction of the others. However, as predicted from the in vitro neutralization experiment using rabbit antisera, transduction with the Pan 6-based vector was not attenuated by previous exposure to any of the other adenoviruses tested.
DISCUSSION
The utility of adenoviral vectors for gene therapy has been diminished because of immune responses to the vector and vector-encoded proteins. This has led to a shift in types of therapeutic applications being considered for adenoviruses, from gene therapy to their use as vaccine carriers. Indeed, vectors based on human AdHu5 have shown tremendous promise in activating T and B cell responses against vector-encoded antigens (Xiang et al., 1996; Sullivan et al., 2000; Tims et al., 2000) .
Nabel and colleagues were able to achieve protection in cynomolgus macaques to lethal doses of Ebola virus after a single vaccination with human AdHu5 expressing two Ebola gene products (Sullivan et al., 2003) . The most advanced application of Ad-based vaccines is for human immunodeficiency virus (HIV), for which Merck and Co. is in late-stage clinical trials (Casimiro et al., 2003; Shiver, 2003) . An important limitation of the current approach is the problem of neutralizing antibodies against the vaccine carrier, which in the case of human AdHu5 is present in up to 80% of the human population as a result of natural infections (Vogels et al., 2003) . Furthermore, a second administration of a vector of the same serotype, in the context of a vaccine boost or another therapeutic application, would be substantially compromised.
Our approach to partially addressing the problem of neutralizing immunity against the vector was to develop adenoviral vectors generated from serotypes not present or prevalent in human populations. A vector based on the chimpanzee virus C68 (Pan 9) was created by homologous recombination in 293 cells and shown to activate T and B cell immunity in mice to HIV Gag and rabies glycoprotein,respectively, as efficiently as do human AdHu5-based vectors (Xiang et al., 2002; Fitzgerald et al., 2003) . Furthermore, we showed that the activity of the ROY ET AL. a Rabbits were immunized with intramuscular injections of 10 13 particles of each of the chimpanzee adenoviruses and boosted 34 days later with the same dose with Freund's incomplete adjuvant. Sera were analyzed for the presence of neutralizing antibodies by incubating serial 2-fold dilutions with 10 9 genome copies of each appropriate chimpanzee adenoviral vector expressing GFP and testing for the attenuation of GFP expression when applied to 293 cells. The serum dilution that produced a 50% reduction of GFP expression was scored as the neutralizing antibody titer against that particular virus. a Prevalence of neutralizing antibodies against chimpanzee adenoviruses Pan 5, Pan 6, Pan 7, and Pan 9 was determined by a virus neutralizationassay using vectors AdC5GFP, AdC6GFP, AdC7GFP, and AdC68GFP. Sera from 51 normal human subjects as well as sera from 52 rhesus macaques and 20 chimpanzees were tested at a dilution of 1:20 for their ability to neutralize the infectivity of each of the viruses as described in Materials and Methods. The prevalence of neutralizing antibody in human serum samples against AdHu5 was also tested, using the AdHu5GFP vector.
AdC68 (Pan 9) vectors was not diminished in the presence of immunity to AdHu5. This report expands the initial work by developing vectors based on three additional chimpanzee adenoviruses and does so through the use of molecular clones.
When considering the development of novel adenovirusbased vectors, we established a number of criteria. The vectors should not be neutralized by human sera and should be serologically distinct from one another so as not to cross-neutralize. It is essential that the vectors be created through molecular clones to eliminate the possibility of contamination by adventitious agents such as prions or viruses resident to the source animals (Rogers et al., 1967; Basnight et al., 1971) . Working from infectious clones based on plasmids also assures clonality of the product. It would be enormously helpful if the vectors could be grown in sufficient yields in cell lines currently used for the growth of human AdHu5 vectors. Finally, the final product should be potent and relatively free of replication-competent adenovirus.
With the development of vectors based on the four chimpanzee adenoviruses, we have achieved our objectives. None of the vectors are appreciably neutralized by human sera and at least two serologically distinct groups have emerged (AdC5, AdC7, and AdC68 versus AdC6). All vectors are created from molecular clones that are easily engineered to incorporate multiple deletions such as E1 and E3 and their growth in HEK 293-derived cells is impressive. We have not detected replicationcompetent adenovirus in the final preparations, presumably because of the sequence dissimilarity between E1 in 293 cells and the flanking sequence in the vectors. The issue of vector potency needs further study in light of the increased particleto-PFU measurements. The fact that the in vitro transduction efficiencies of the chimpanzee adenoviral vectors are not appreciably different from those of human AdHu5 vectors suggests that this may be more a problem of the assay and the cell line rather than the vectors. Another issue relates to the suitability of using nonhuman viruses as vectors/vaccine carriers in humans. The dissimilarity in sequence between the chimpanzee-derived viruses and the common subgroup C human adenovirus is an advantage in that recombination in the context of production has not been observed, thereby diminishing the problem of replication-competent virus. We would predict that in vivo recombination with this group of human adenoviruses would be unlikely as well. The lower transduction of hepatocytes observed with the chimpanzee adenoviruses might diminish hepatic toxicity in applications where systemic dissemination of the vector is possible, providing another safety advantage. Although the adenoviruses Pan 5, Pan 6, and Pan 7 were isolated from chimpanzees, we cannot rule out the possibility that they, or closely related isolates, also contribute to natural infections in humans. In fact, Pan 5, Pan 6, Pan 7, and Pan 9 are structurally similar to human adenovirus serotype 4 of the subgroup E family. Safety issues related to the use of CHIMPANZEE ADENOVIRAL VECTORS
FIG. 8.
In vivo cross-neutralization of adenoviral vectors of different serotypes. C57BL/6 mice were immunized intramuscularly with either PBS or 10 11 particles of E1-deleted AdHu5CMVLacZ, AdC5CMVLacZ, AdC6CMVLacZ, AdC7CMVLacZ, or AdC68CMVLacZ vectors (shown as H5, C5, C6, C7, and C68, respectively). One month later, each group of animals that received PBS or LacZ vector was treated intravenously with E1-deleted AdHu5, AdC5, AdC6, AdC7, or AdC68 vector expressing A1AT. Serum A1AT levels in each group of animals were measured on day 3 after the second injection and are represented on the y axis.
these vectors for human applications ultimately will require careful preclinical assessments irrespective of their primary species of origin. Application of these novel chimpanzee adenoviruses as vaccine carriers against a number of biological weapons, infectious diseases, and cancers is underway.
